Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of lower doses of primaquine compared to the dose recommended by the WHO for reducing P. falciparum gametocytes in the infected human host to prevent transmission of falciparum malaria to the anopheles mosquito vector.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine
• Collaborator: Wellcome Trust
• Treatments: Primaquine

Criteria

Inclusion Criteria:

• Age >/= 1 year and
• Weight over 10kg

• Fever >38 degrees C (tympanic) or history of fever in the last 24 hours

• P. falciparum parasitaemia <500 000/µl

• Normal G6PD enzyme function

Exclusion Criteria:

• Enrolled in another study

• Evidence of severe illness/ danger signs

• Known allergy to study medications

• Haemoglobin < 8g/dL)

• Started menstruation

• Pregnancy or breastfeeding

• Primaquine taken within the last 4 weeks

• Blood transfusion within the last 90 days

• Non-falciparum malaria co-infection